Vaxart Stock Price - VXRT

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Vaxart Inc VXRT NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00155 0.24% 0.65255 0.6757 0.64 0.6456 0.651 11:21:10
Bid Price Ask Price Spread Spread % News
0.6451 0.66 0.0149 2.26% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
179 42,510 $ 0.6636458 $ 28,212 294,519 0.5223 - 7.60
Last Trade Time Type Quantity Stock Price Currency
11:22:15 8 $ 0.6525 USD

Vaxart Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 10.30M 15.79M $ -18.01M -2.34 - 13.22M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 10.00 16.30%

more financials information »

Vaxart News

Loading Messages....

Latest VXRT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VXRT Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week0.6810.77980.60120.6869749k-0.02845-4.18%
1 Month0.650.77980.60120.6907315k0.002550.39%
3 Months0.73220.9220.550.6875199k-0.07965-10.88%
6 Months1.6150.52231.5165636k-0.95745-59.47%
1 Year2.817.60.52232.3052442k-2.15745-76.78%
3 Years15.62220.52234.9683313k-14.96745-95.82%
5 Years24.86330.52237.5781216k-24.20745-97.38%

Vaxart Description

Vaxart Inc is a biopharmaceutical company. It is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The company has three product candidates which are; vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics; BTA585, an oral fusion protein inhibitor for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in for condyloma caused by human papillomavirus.


Your Recent History
NASDAQ
VXRT
Vaxart
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.